$43.85
0.90% yesterday
NYSE, Nov 25, 10:00 pm CET
ISIN
US03770N1019
Symbol
APGE
Sector
Industry

Apogee Therapeutics Stock price

$43.85
-9.38 17.62% 1M
-4.18 8.70% 6M
+15.91 56.94% YTD
+26.99 160.08% 1Y
+22.62 106.55% 3Y
+22.62 106.55% 5Y
+22.62 106.55% 10Y
NYSE, Closing price Mon, Nov 25 2024
+0.39 0.90%
ISIN
US03770N1019
Symbol
APGE
Sector
Industry

Key metrics

Market capitalization $2.56b
Enterprise Value $2.05b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 3.49
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-178.14m
Free Cash Flow (TTM) Free Cash Flow $-134.53m
Cash position $526.05m
EPS (TTM) EPS $-2.73
P/E forward negative
Short interest 17.71%
Show more

Is Apogee Therapeutics a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

Apogee Therapeutics Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Apogee Therapeutics forecast:

7x Buy
100%

Analyst Opinions

7 Analysts have issued a Apogee Therapeutics forecast:

Buy
100%

Financial data from Apogee Therapeutics

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
- -
-
100%
- Direct Costs 0.11 0.11
-
-
-0.11 -0.11
-
-
- Selling and Administrative Expenses 41 41
-
-
- Research and Development Expense 137 137
-
-
-178 -178
-
-
- Depreciation and Amortization 0.11 0.11
-
-
EBIT (Operating Income) EBIT -178 -178
-
-
Net Profit -147 -147
-
-

In millions USD.

Don't miss a Thing! We will send you all news about Apogee Therapeutics directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Apogee Therapeutics Stock News

Neutral
GlobeNewsWire
8 days ago
Company to highlight progress across its pipeline and showcase its path to reshaping the standard of care in I&I with best-in-class monotherapy and combination treatments Company to highlight progress across its pipeline and showcase its path to reshaping the standard of care in I&I with best-in-class monotherapy and combination treatments
Positive
Seeking Alpha
16 days ago
Apogee Therapeutics' APG777 shows promise in treating atopic dermatitis with less frequent dosing and potential applications in asthma, COPD, and psoriasis. APGE's investigational pipeline includes APG808 and APG990, targeting different inflammatory pathways, enhancing its potential in the I&I market. APGE's strong cash runway and multiple upcoming catalysts, including Phase 2 results for APG77...
Neutral
GlobeNewsWire
22 days ago
SAN FRANCISCO and WALTHAM, Mass., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD) a...
More Apogee Therapeutics News

Company Profile

Apogee Therapeutics, Inc. operates as a biotechnology company. It offers treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD) and related inflammatory and immunology (I&I) indications. The company was founded in February 2022 and is headquartered in Waltham, MA.

Head office United States
CEO Michael Henderson
Founded 2022
Website www.apogeetherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today